Incidence, risk factors and re-exacerbation rate of severe asthma exacerbations in a multinational, multidatabase pediatric cohort study by Engelkes, M. (Marjolein) et al.
Pediatr Allergy Immunol. 2020;00:1–10.    |  1wileyonlinelibrary.com/journal/pai
 
Received: 25 October 2019  |  Revised: 4 February 2020  |  Accepted: 6 February 2020
DOI: 10.1111/pai.13237  
O R I G I N A L  A R T I C L E
Incidence, risk factors and re-exacerbation rate of severe 
asthma exacerbations in a multinational, multidatabase 
pediatric cohort study
Marjolein Engelkes1 |   Esme J. Baan1  |   Maria A. J. de Ridder1 |   Elisabeth Svensson2 |   
Daniel Prieto-Alhambra3,4 |   Francesco Lapi5 |   Carlo Giaquinto6 |   Gino Picelli7 |   
Nada Boudiaf8 |   Frank Albers9  |   Lee A. Evitt10 |   Sarah Cockle10 |   Eric Bradford10 |   
Melissa K. Van Dyke11  |   Robert Suruki12 |   Peter Rijnbeek1 |    
Miriam C. J. M. Sturkenboom13 |   Hettie M. Janssens14 |   Katia M. C. Verhamme1,15
1Medical Informatics, ErasmusMC, Rotterdam, The Netherlands
2Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
3Jordi Gol Primary Care Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain
4Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
5SIMG, Florence, Italy
6University of Padova, Padova, Italy
7, Pedianet, Padova, Italy
8Research and Development, GlaxoSmithKline, Middlesex, UK
9Research and Development, GlaxoSmithKline, Research Triangle Park, NC, USA
10Research and Development, GlaxoSmithKline, Brentford, UK
11Research and Development, GlaxoSmithKline, Collegeville, PA, USA
12UCB Biosciences, Raleigh, NC, USA
13Julius Global Health, Utrecht University Medical Center, Utrecht, The Netherlands
14Pediatrics div Respiratory Medicine and Allergology, ErasmusMC- /Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The 
Netherlands
15Department of Infection Control & Epidemiology, OLV Hospital, Aalst, Belgium
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. Pediatric Allergy and Immunology published by John Wiley & Sons Ltd
The peer review history for this article is available at https://publons.com/publon/10.1111/pai.13237 
Correspondence
Katia Verhamme, Department of Medical 
Informatics, ErasmusMC, Dr Molewaterplein 
50, 3000 CA Rotterdam, The Netherlands.
Email: k.verhamme@erasmusmc.nl
Present address
Frank Albers, Avillion US Inc., Northbrook, 
IL, USA
Funding information
GSK (PRJ2284) and ZonMw (113201006).
Editor: Ömer Kalaycı
Abstract
Background: There are sparse real-world data on severe asthma exacerbations (SAE) 
in children. This multinational cohort study assessed the incidence of and risk factors 
for SAE and the incidence of asthma-related rehospitalization in children with asthma.
Methods: Asthma patients 5-17 years old with ≥1 year of follow-up were identified 
in six European electronic databases from the Netherlands, Italy, the UK, Denmark 
and Spain in 2008-2013. Asthma was defined as ≥1 asthma-specific disease code 
within 3 months of prescriptions/dispensing of asthma medication. Severe asthma 
was defined as high-dosed inhaled corticosteroids plus a second controller. SAE was 
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1  | INTRODUC TION
Asthma is an important public health problem and is responsible for 
a high number of missed school and work days; moreover, it can be 
associated with significant limitations on physical, social and profes-
sional/student aspects of life when it is not controlled.1,2 Asthma 
exacerbations represent a decline in lung function with worsening of 
respiratory symptoms such as shortness of breath, cough and/or chest 
tightness.2 According to a joint statement of the European Respiratory 
Society and the American Thoracic Society, a severe asthma exacerba-
tion (SAE) is defined as the use of systemic corticosteroids, emergency 
department (ED) visit or hospitalization all for reason of asthma.3
There are scarce international data on the incidence of SAE in 
asthma children in the general population. The Asthma Insights and 
Reality in Europe (AIRE) study was conducted in 1999, in which 
asthma patients from 7 different European countries were ques-
tioned during a telephone interview. It showed differences in SAE 
rates between countries, as 7%-40% of children with asthma re-
ported an ED visit for asthma and 3%-12% were hospitalized in the 
previous year.4 As this study used interview data, it was susceptible 
to recall bias. Randomized controlled trials can also provide data on 
the incidence of severe asthma exacerbations, but these numbers 
tend to be much lower than in real life due to strict inclusion and 
exclusion criteria and short follow-up.5 Risk factors for SAEs have 
been studied primarily in adults, and thus, data in children are scarce.
Currently, we still lack reliable instruments or biomarkers to pre-
dict SAE in children. Several studies found that the best predictor of 
future SAE was a history of a previous SAE.6,7 This implies that the 
risk of rehospitalization is probably high.
In this study, we aimed to estimate real-world incidence rates of 
and risk factors for SAEs, as well as to study the rate and cumulative 
incidence of asthma rehospitalization in children with asthma and 
severe asthma, using one protocol and harmonized methods with 
regard to data extraction and data analysis, across multiple data 
sources from five different European countries.
2  | METHODS
A retrospective cohort study was conducted using data from six 
European electronic healthcare databases, namely the Integrated 
Primary Care Information Project (IPCI) from the Netherlands, the 
Health Search Database (HSD) and Pedianet from Italy, Clinical 
Practice Research Datalink (CPRD) from the UK, the Sistema 
d'Informació per al Desenvolupament de la Investigació en Atenció 
Primària (SIDIAP) from Spain and the Aarhus University Prescription 
defined by systemic corticosteroids, emergency department visit and/or hospitaliza-
tion all for reason of asthma. Risk factors for SAE were estimated by Poisson regres-
sion analyses.
Results: The cohort consisted of 212 060 paediatric asthma patients contributing to 
678 625 patient-years (PY). SAE rates ranged between 17 and 198/1000 PY and were 
higher in severe asthma and highest in severe asthma patients with a history of ex-
acerbations. Prior SAE (incidence rate ratio 3-45) and younger age increased the SAE 
risk in all countries, whereas obesity, atopy and GERD were a risk factor in some but 
not all countries. Rehospitalization rates were up to 79% within 1 year.
Conclusions: In a real-world setting, SAE rates were highest in children with severe 
asthma with a history of exacerbations. Many severe asthma patients were rehospi-
talized within 1 year. Asthma management focusing on prevention of SAE is impor-
tant to reduce the burden of asthma.
K E Y W O R D S
asthma: epidemiology, asthma: risk factors, epidemiology: prevalence
Key Message
There are few studies on the real-life incidence of severe 
asthma exacerbations in children and the few available 
strongly vary in study design. In this large international 
retrospective cohort study we investigated the incidence 
of and risk factors for severe asthma exacerbations in 6 
European databases using one single protocol and har-
monized methods for data extraction and data analysis. 
We observed exacerbation rates ranging between 17 
and 198/1000 person-years in the different databases 
with high rehospitalization rates. This underscores the 
importance of enhanced patient care in children with 
asthma to achieve the ultimate goal of preventing asthma 
exacerbations.
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Database (Aarhus) from Denmark. Detailed descriptions of these 
databases have been published before and are available in the 
Appendix S1.8-13 All databases comprise detailed information on 
drug prescriptions or dispensing, outpatient diagnoses and hospitali-
zations, comorbidity and measurement data (eg laboratory results, 
spirometry, BMI). While in most databases children of all ages are 
captured, in Italy for children 0-6 years old all primary care is pro-
vided by paediatricians, and parents can choose between a paedia-
trician and a GP for children 6-16 years of age. Therefore, Pedianet 
(primary care paediatrician data) tends to contain younger children, 
while HSD (GP data) tends to capture older children.
All participating databases comply with EU guidelines on 
the use of medical data for research and are registered in the 
European Network of Centres for Pharmacoepidemiology and 
Pharmacovigilance (ENCePP) database.14 In all 5 countries, the study 
protocol was approved by their local institutional review board.
2.1 | Cohort definition
A cohort of patients with asthma was determined in each data-
base within the study period (1 January 2008-31 December 2013). 
To enter the cohort, patients needed to be 5-17 years old, with a 
minimum of 1-year database history and diagnosed with asthma. 
Asthma was defined as physician-diagnosed asthma based on 
the presence of at least one asthma-specific disease code (see 
Appendix S1) in combination with prescriptions/dispensing of 
asthma medications within 3 months of the asthma disease code. 
Asthma medications consisted of the following: inhaled corti-
costeroids (ICS), short-acting β2 agonists (SABA), long-acting β2 
agonists (LABA), fixed combination of ICS + LABA, leukotriene 
receptor antagonist, short-acting muscarinic antagonist (SAMA), 
fixed combination of SABA + SAMA, xanthines, systemic corti-
costeroids for the treatment of asthma, and anti-IgE treatment. 
Information on drug use was retrieved by an ATC-specific search 
from the drug prescription and/or drug dispensing records. Based 
on the first date of an asthma disease code, patients were catego-
rized into prevalent or incident asthma.
Within the cohort of patients with asthma, a subcohort of pa-
tients with severe asthma was nested. According to international 
guidelines, severe asthma was defined as asthma requiring treat-
ment with high-dose ICS (as defined in the Global Initiative of 
Asthma (GINA); see Appendix S1) plus a second controller and/or 
systemic corticosteroids for at least 120 consecutive days.2,15 To 
account for immortal time bias, the start date of severe asthma was 
day 120 of high-dose ICS use.
2.2 | Follow-up
Follow-up started at the latest date of the following: the start of 
the study period, diagnosis of (severe) asthma, age of 5 years or 
after reaching 365 days of database history. Follow-up ended when 
leaving the database, reaching the age of 18, death or end of the 
study period, whichever came first.
2.3 | Outcomes
An SAE was defined as any of the following: use of systemic corti-
costeroids, ED visit or hospitalization, all for worsening of asthma. 3 
The indication of corticosteroid use was retrieved from the prescrip-
tion/dispensing file or through an automated search on asthma (ex-
acerbation) disease codes in a 7-day window around the prescription 
date. Continuous use of systemic corticosteroids, defined as con-
secutive use of at least 30 days, was not considered as an SAE. If the 
time between exacerbations, of whatever type, was <7 days, it was 
considered to be one single exacerbation.
Rehospitalization was defined as an asthma-related hospi-
talization following a previous asthma-related hospitalization. 
Hospitalizations were based on primary discharge diagnosis codes 
in SIDIAP, Aarhus and CPRD and were based on manual validation of 
discharge letters in the other databases.
2.4 | Covariates
We investigated the prevalence of the following comorbidities at 
the start of follow-up and at each exacerbation, using the complete 
medical history: atopy (allergic rhinitis and/or atopic eczema/der-
matitis), chronic rhinosinusitis, nasal polyposis, gastro-oesophageal 
reflux disease (GERD), obesity and diabetes mellitus. In addition, we 
investigated whether or not patients had a history of exacerbations. 
History of exacerbations was defined as ≥2 SAEs in the 1 year prior 
to entering the (severe) asthma cohort. If patients had <12 months 
prior to asthma diagnosis or the start of severe asthma, 1 exacerba-
tion or more in the 6 months prior fulfilled the criterion. We also 
investigated age and gender as covariates.
2.5 | Analysis
The exacerbation rates were calculated by dividing the number of 
exacerbations by the respective number of person-years of follow-
up and additionally stratified by gender and age in years.
Asthma rehospitalization rates in predefined follow-up time 
windows (30, 180 and 365 days following a previous hospitaliza-
tion) were calculated. If a patient had more than one exacerbation 
during that time window, each exacerbation contributed to the nom-
inator. Furthermore, from these rates cumulative incidences were 
calculated.
Heterogeneity was quantified by the I2 statistics to assess if it 
was appropriate to perform a meta-analysis on the overall SAE rates 
estimated in the databases.
Risk factors for exacerbations were assessed by Poisson re-
gression analyses, adjusting for age, gender and their interaction. 
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A multivariate model was fitted using the following covariates: age, 
gender, comorbidity (atopy, obesity, GERD), history of exacerba-
tions and the interaction between age and gender and between age 
and history of exacerbations. These analyses were repeated after 
stratification for age: for children 5-11 years old and for children 
12-17 years old. Analyses were conducted using SAS® version 9.4.
3  | RESULTS
The cohort comprised 212 060 children with asthma contributing 
678 625 patient-years (PY). In total, 14 283 children (6.7%, ranging from 
1.6% to 18.3% across databases) with severe asthma were identified.
The mean age at the start of follow-up was 10.4 years (ranging 
between 7.2 and 14.8 years across databases), and a male prepon-
derance was observed. The prevalence of atopy was 9.6% in Aarhus 
and ranged between 24.1% and 43.6% in the other databases. In all 
databases, the prevalence of atopy, GERD and obesity was higher in 
patients with severe asthma. (Tables 1 and 2).
Of all asthma patients, depending on the database, 2.8%-29.3% 
had at least one exacerbation during the follow-up. In HSD, SIDIAP 
and PEDIANET, SAE mostly comprised use of systemic corticoste-
roids (89%-100%), while in IPCI, Aarhus and CPRD, this proportion 
was 57%, 25% and 77%, respectively. Large differences between 
databases in incidence rates (IR) of SAE were observed especially 
for the younger age. The overall SAE rates ranged between 17 and 
198/1000 PY and were higher in severe asthma patients (range 46-
375/1000 PY). SAE rates decreased with age, from age 5 onwards, 
and this was significant for all databases. (Figure 1 and Table 3) From 
adolescence on, higher IRs of SAE were observed for women com-
pared to men in CPRD, SIDIAP, IPCI and Aarhus. (Figure 1) The IR 
ranged between 11 and 131/1000 PY in patients without a history of 
exacerbations and was higher in children with severe asthma espe-
cially with a history of exacerbations (283-1000/1000 PY). (Figure 2 
and Table S1) As the heterogeneity of exacerbation rates was sub-
stantial (I2 > 99%), it was not appropriate to pool the data.
3.1 | Risk factors for severe asthma exacerbations
After adjustment for age, gender and their interaction, having atopy, 
GERD and obesity increased the risk of SAE in some databases. 
(Table S2) In the multivariate model, the same risk factors remained, 
but risk estimates were lower. (Table 3) Additionally, the interaction 
between age and a history of exacerbations showed that in some da-
tabases, the risk associated with a history of exacerbations increased 
TA B L E  1   Baseline characteristics of total asthma cohorts
 CPRD (n, %) SIDIAP (n, %) IPCI (n, %) AARHUS (n, %) PEDIANET (n, %) HSD (n, %)
Total 124 554 30 749 31 705 12 521 8264 4267
Female 51 667 (41.5) 12 357 (40.2) 13 262 (41.8) 4681 (37.4) 2980 (36.1) 1665 (39.0)
Male 72 887 (58.5) 18 392 (59.8) 18 443 (58.2) 7840 (62.6) 5284 (63.9) 2602 (61.0)
Age (mean, min-max) 10.9 (5.0-17.9) 8.9 (5.0-17.9) 10.2 (5.0-17.9) 9.3 (5.0-17.9) 7.2 (5.0-14.0) 14.8 (6.6-17.9)
Severe asthma 9162 (7.4) 1139 (3.7) 1858 (5.9) 1207 (9.6) 137 (1.7) 780 (18.3)
Incident asthma 23 743 (19.1) 13 062 (42.5) 4604 (14.5) 1392 (11.1) 1892 (22.9) 1302 (30.5)
Prevalent asthma 100 811 (80.9) 17 687 (57.5) 27 101 (85.5) 11 129 (88.9) 6372 (77.1) 2965 (69.5)
History of exacerbations
Yes 5276 (4.2) 2625 (8.5) 241 (0.8) 408 (3.3) 196 (2.4) 321 (7.5)
No 119 278 (95.7) 28 124 (91.5) 31 464 (99.2) 12 113 (96.7) 8068 (97.6) 3946 (92.5)
Atopy 54 356 (43.6) 9767 (31.8) 11 602 (36.6) 1200 (9.6) 1990 (24.1) 961 (22.5)
GERD 3247 (2.6) 248 (0.8) 510 (1.6) 103 (0.8) 146 (1.8) 55 (1.3)
Diabetes mellitus 294 (0.2) 42 (0.1) 81 (0.3) 43 (0.3) 0 7 (0.2)
Obesity 24 742 (19.9) 12 828 (41.7) 1518 (5.0) 205 (1.6) 3977 (48.1) 265 (6.2)
Chronic rhinosinusitis 4917 (3.9) 33 (0.1) 112 (0.4) 0 0 38 (0.9)
Nasal polyposis 228 (0.2) 0 13 (0.0) 8 (0.1) 0 0
Patients with ≥1 
exacerbation
12 638 (10.2) 8968 (29.3) 871 (2.8) 756 (6.0) 724 (8.8) 855 (20.0)
Asthma 
exacerbations (n)
19 530 18 808 1290 1020 1031 1461
Systemic 
corticosteroids 
(n, %)
15 049 (77.0) 17 323 (92.1) 739 (57.3) 252 (24.7) 918 (89.0) 1460 (99.9)
ED/ hospitalization 
(n, %)
4481 (23.0) 1485 (7.9) 551 (42.7) 768 (75.3) 113 (11.0) 1 (0.1)
Abbreviations: ED, emergency department; GERD, gastro-oesophageal reflux disease.
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with increasing age, and in others, this risk decreased. After strati-
fication for age category, for female gender in 5- to 11-year-olds a 
decreased risk was found, while in 12- to 17-year-olds there was 
an increased risk. These findings were less prominent in Pedianet 
and HSD, possibly due to the limited age range in these databases. 
No other distinct differences between the age categories were ob-
served (see Appendix S1).
3.2 | Rehospitalization following previous 
hospitalization for asthma exacerbation
Rehospitalization rates decreased with time following index hospi-
talization. The asthma rehospitalization rate was highest in SIDIAP 
(within 1 month: 13.7/10 PY in children with asthma and 88.3/10 PY 
in children with severe asthma), whereas in the other databases the 
TA B L E  2   Baseline characteristics of severe asthma cohorts
 CPRD (n, %) SIDIAP (n, %) IPCI (n, %) AARHUS (n, %) PEDIANET (n, %) HSD (n, %)
Total 9162 1139 1858 1207 137 780
Female 3705 (40.4) 481 (42.2) 806 (43.4) 406 (33.6) 34 (24.8) 292 (37.4)
Male 5457 (59.6) 658 (57.8) 1052 (56.6) 801 (66.4) 103 (75.2) 488 (62.6)
Age (mean, 
min-max)
11.0 (5.0-17.9) 8.60 (5.0-17.9) 13.1 (5.0-17.9) 10.4 (5.0-17.9) 9.3 (5.0-12.9) 14.5 (2.4)
Incident asthma 436 (4.8) 164 (14.4) 122 (6.6) 102 (8.5) 6 (4.4) 79 (10.1)
Prevalent asthma 8726 (95.2) 975 (85.6) 1736 (93.4) 1105 (91.5) 131 (95.6) 701 (89.9)
History of exacerbations
Yes 562 (6.1) 215 (18.9) 49 (2.6) 40 (1.7) 1 (0.8) 55 (7.1)
No 8600 (93.9) 924 (81.1) 1809 (97.4) 1167 (98.3) 136 (99.3) 725 (92.9)
Atopy 4724 (51.6) 407 (35.7) 789 (42.5) 194 (16.1) 54 (39.4) 190 (24.4)
GERD 375 (4.1) 23 (2.0) 34 (1.8) 14 (1.2) 3 (2.2) 16 (2.1)
Diabetes mellitus 25 (0.3) 2 (0.2) 4 (0.2) 6(0.5) 0 2 (0.3)
Obesity 2541 (27.7) 522 (45.8) 174 (9.4) 45 (3.7) 60 (43.8) 57 (7.3)
Chronic 
rhinosinusitis
475 (5.2%) 3 (0.3%) 12 (0.6%) 0 0 7 (0.9%)
Nasal polyposis 31 (0.3%) 0 3 (0.2%) 1 (0.1%) 0 0
Abbreviation: GERD, gastro-oesophageal reflux disease
F I G U R E  1   SAE rate (per 1000 PY) with 95% CI by age and gender in the total asthma cohort per database
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rehospitalization rate within the first month ranged between 5.4 and 
7.7/10 PY in children with asthma and between 14.3 and 15.8/10 PY 
in children with severe asthma.
The cumulative incidence of rehospitalization within 1 year was 
17%-29% in children with asthma, whereas this was much higher, 
namely 33%-79%, in patients with severe asthma. (Table 4) No data 
are presented for HSD and Pedianet as the number of children being 
hospitalized for asthma exacerbation was too low.
4  | DISCUSSION
In this study, the overall exacerbation rate in children with asthma 
ranged between 17 and 198/1000 PY across databases, increased 
in children with severe asthma (range 46-375/1000 PY) and was 
the highest in those with severe asthma with a history of exacer-
bations (283-1000/1000 PY). Rehospitalization following a previ-
ous hospitalization was high, both in the overall asthma cohort, 
namely 17%-29% being rehospitalized in a year, and especially in 
children with severe asthma, as up to 79% were rehospitalized 
within a year.
We observed large differences in incidence rate of SAE, espe-
cially for the youngest age categories, and also large differences in 
the type of SAE. Large differences in exacerbation rates between 
European countries have previously been observed in other stud-
ies that used questionnaires or interviews to collect data instead of 
healthcare databases. In line with our results, these studies showed 
higher severe exacerbation rates in Italy and Spain than in the 
UK, and higher rates of emergency care in Spain than in the UK. 
In the Asthma Insights and Reality in Europe (AIR) survey, hospital-
ization rates in children were higher in Spain and Italy than in The 
Netherlands and the UK. 16-18 In these studies, many reasons for 
these differences were suggested: differences in disease manage-
ment such as asthma prevention plans, lung function measurement, 
and difference in drug prescriptions, compliance with therapy, envi-
ronmental differences and cultural differences such as perception of 
disease burden and healthcare-seeking behaviour.
Our exacerbation rates are in line with a recent study by Suruki 
et al investigating SAE in adolescent and adult asthma patients.19 
They reported a mean exacerbation rate in asthma patients 
12-17 years old of 156/1000 PY based on US claims data and of 
77/1000 PY using CPRD data. Comparison with other studies is dif-
ficult, as most of these only investigated hospitalizations for asthma, 
included systemic corticosteroids irrespective of the indication of 
use or investigated a selective population.17,19-24
Our observation on frequent rehospitalization is in line with data 
from two cohort studies on hospitalizations for children with asthma 
in the United States which observed that 17% and 22% of hospital-
ized children were readmitted within 365 days.25,26 The risk fac-
tors for SAE were a previous SAE, male gender, youngest age and 
atopy. In agreement with published literature, in our study a previous 
exacerbation was the best predictor of a subsequent asthma exacer-
bation.27-29 Other published risk factors for asthma exacerbations T
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such as obesity and GERD could not be confirmed as risk factor in all 
participating databases.30,31
As for all observational studies, our study has strengths and 
limitations. Major strengths include the large number of children 
with asthma included in our cohort, from 6 different European 
databases in 5 countries, using a single protocol and harmonized 
methods for data extraction and data analysis. Detailed informa-
tion on important covariates such as drug exposure and underly-
ing comorbidity and on lifestyle factors was collected. The use of 
real-life data in a heterogeneous asthmatic population increases 
the external validity of our findings as our data are highly rep-
resentative of actual practice conditions and likely to minimize 
Hawthorne and similar effects.32
However, as this is an observational study, using data from elec-
tronic healthcare databases, there is always the potential of bias 
and/or confounding.
First, we did report large differences in the incidence rates of 
SAE between countries.
For those databases where automatic linkage with hospital data 
was available (CPRD, SIDIAP and Aarhus), misclassification of ED 
visits/hospitalization is unlikely. For the other databases, hospital-
ization or ED visit was retrieved either via disease-specific codes in 
combination with codes for hospitalization (HSD and Pedianet) or via 
review of the discharge letters (IPCI). For prescriptions of systemic 
steroids, only those with an indication for asthma registered in the 
database were included. If practices did not report the indication of 
use or did not report disease codes around the prescription date, we 
might have underreported the incidence rate. Similar underreporting 
might have occurred if patients used previously collected systemic 
corticosteroids.
Also, the large differences in SAE rates might be due to inter-
national differences in the use of systemic steroids. For example, in 
Spain (SIDIAP), a large incidence of SAE based on use of systemic 
steroids was observed in young children. Despite the fact that these 
differences between the databases complicate comparison between 
countries, we believe that it is better to study six different databases 
in one identical way than having six different single database studies 
using different methods because that would make comparison even 
more difficult.
For Aarhus and SIDIAP, dispensing data instead of prescrip-
tion data were used, reducing misclassification of exposure. 
Unfortunately, dosing information is missing in Aarhus and SIDIAP 
and dosing was derived from the strength per device and the time 
window between prescriptions. Of course, this method is prone to 
misclassification, which might explain the relative low proportion of 
severe asthma patients in SIDIAP.
Because of large numbers, manual validation of asthma was not 
feasible and asthma was defined based on the presence of disease 
codes, and thus, potential misclassification of asthma cannot be 
excluded. However, to ensure good quality of health care, GPs are 
trained and requested to enter disease codes fitting the actual pa-
tient's diagnosis.
Furthermore, for each of the comorbidities of interest, diseases 
were mapped through the Unified Medical Language System (UMLS) 
generating a list of disease codes (see Appendix S1) which were 
verified by the databases prior to extraction.33 Still we cannot ex-
clude potential misclassification in case certain disease codes were 
omitted or in case of country-specific differences in disease coding. 
Despite these potential limitations, we were able to give a good re-
flection of exacerbations in the general population and found similar 
trends of risk factors across the databases.
5  | CONCLUSION
In this study, the incidence rates of severe asthma exacerbation 
in children ranged between 17 and 198/1000 PY and increased 
in children with severe asthma. In keeping with previous studies, 
F I G U R E  2   SAE rate (per 1000 PY) with 95% CI by history of exacerbations and severity (severe asthma in Pedianet not presented as low 
numbers)
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the most important risk factor for hospitalization was a previous 
exacerbation.
Rehospitalization for asthma following a previous hospitalization 
was high, especially in children with severe asthma as up to 50% 
were rehospitalized within 1 month and up to 79% within 1 year 
following discharge. This underscores the importance of enhanced 
patient care in children with asthma to achieve the ultimate goal of 
preventing asthma exacerbations.
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